John Shields

Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

Andrew D. Weinberg, Martin-Muy Rivera, Rodney A. Prell et al. · The Journal of Immunology · 2000 · 386 citations · Full text

Life Sciences, Immunology, Oncology +17

Human therapeutic cocaine vaccine: safety and immunogenicity

Thomas R. Kosten, Marc I. Rosen, Julian F. Bond et al. · Vaccine · 2002 · 193 citations

Veterinary Medicine, Immunology, Immunization +11

Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays

Elaine J. Clutterbuck, John Shields, John Gordon et al. · European Journal of Immunology · 1987 · 178 citations

Life Sciences, Immunology, Clinical Immunology +6

Regulation of T Cell Activation In Vitro and In Vivo by Targeting the OX40-OX40 Ligand Interaction: Amelioration of Ongoing Inflammatory Bowel Disease with an OX40-IgG Fusion Protein, But Not with an OX40 Ligand-IgG Fusion Protein

Lisa M. Higgins, Stuart A.C. McDonald, Nigel Whittle et al. · The Journal of Immunology · 1999 · 169 citations · Full text

Life Sciences, Immunology, Pathology +17

Inhibition of an in Vivo Antigen-Specific IgE Response by Antibodies to CD23

Leopoldo Flores‐Romo, John Shields, Yves Humbert et al. · Science · 1993 · 116 citations

Life Sciences, Immunology, Molecular Biology +17